Literature DB >> 5684460

Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice.

F Sorm, J Veselý.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5684460

Source DB:  PubMed          Journal:  Neoplasma        ISSN： 0028-2685            Impact factor:   2.575


× No keyword cloud information.
  28 in total

Review 1.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 2.  The future of epigenetic therapy in solid tumours--lessons from the past.

Authors:  Nilofer Azad; Cynthia A Zahnow; Charles M Rudin; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2013-04-02       Impact factor: 66.675

3.  p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.

Authors:  K P Ng; Q Ebrahem; S Negrotto; R Z Mahfouz; K A Link; Z Hu; X Gu; A Advani; M Kalaycio; R Sobecks; M Sekeres; E Copelan; T Radivoyevitch; J Maciejewski; J C Mulloy; Y Saunthararajah
Journal:  Leukemia       Date:  2011-06-24       Impact factor: 11.528

4.  Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance.

Authors:  L A Michalowsky; P A Jones
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

Review 5.  Epigenetics and innate immunity: the 'unTolld' story.

Authors:  Conor Hennessy; Declan P McKernan
Journal:  Immunol Cell Biol       Date:  2016-02-29       Impact factor: 5.126

6.  DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Authors:  Min Chen; Daniel Shabashvili; Akbar Nawab; Sherry X Yang; Lisa M Dyer; Kevin D Brown; Melinda Hollingshead; Kent W Hunter; Frederic J Kaye; Steven N Hochwald; Victor E Marquez; Patricia Steeg; Maria Zajac-Kaye
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

Review 7.  Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors.

Authors:  Michael Daskalakis; David Brocks; Yi-Hua Sheng; Md Saiful Islam; Alzbeta Ressnerova; Yassen Assenov; Till Milde; Ina Oehme; Olaf Witt; Ashish Goyal; Alexander Kühn; Mark Hartmann; Dieter Weichenhan; Manfred Jung; Christoph Plass
Journal:  Cell Cycle       Date:  2018-04-30       Impact factor: 4.534

8.  Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine.

Authors:  R L Momparler; J Samson; L F Momparler; G E Rivard
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer.

Authors:  Ju Hwan Cho; Filiz Oezkan; Michael Koenig; Gregory A Otterson; James Gordon Herman; Kai He
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

Review 10.  Epigenetic therapy in gastrointestinal cancer: the right combination.

Authors:  Eihab Abdelfatah; Zachary Kerner; Nainika Nanda; Nita Ahuja
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.